---
document_datetime: 2023-09-21 20:01:12
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zeposia-epar-all-authorised-presentations_en.pdf
document_name: zeposia-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8908809
conversion_datetime: 2025-12-27 20:20:04.618876
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength          | Pharmaceutical Form   | Route of Administration   | Immediate Packaging     | Pack size                                               |
|------------------|-------------------|-------------------|-----------------------|---------------------------|-------------------------|---------------------------------------------------------|
| EU/1/20/1442/001 | Zeposia           | 0.23 mg + 0.46 mg | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/Alu) | Initiation pack: 7 capsules (4 x 0.23 mg + 3 x 0.46 mg) |
| EU/1/20/1442/002 | Zeposia           | 0.92 mg           | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/Alu) | 28 capsules                                             |
| EU/1/20/1442/003 | Zeposia           | 0.92 mg           | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/Alu) | 98 capsules                                             |